Sorrento Therapeutics Inc. buy tamam
Summary
This prediction ended on 04.03.19 with a price of €1.87. The BUY prediction by tamam for Sorrento Therapeutics Inc. performed very badly with a performance of -71.84%. tamam has 50% into this predictionPerformance without dividends (%)
Name | 1w | 1m | 1y | 3y |
---|---|---|---|---|
Sorrento Therapeutics Inc. | - | - | - | - |
iShares Core DAX® | -1.471% | 1.895% | 25.178% | 22.236% |
iShares Nasdaq 100 | -0.486% | 4.395% | 29.415% | 42.175% |
iShares Nikkei 225® | -2.115% | 2.450% | 20.561% | 6.454% |
iShares S&P 500 | 0.394% | 3.118% | 29.456% | 42.672% |
Comments by tamam for this prediction
In the thread Sorrento Therapeutics Inc. diskutieren
SRNE has some earlier stage compounds in its pipeline targeting Immuno-Oncology and Pain Management.
Oppenheimer's analyst had this to say about his positive view on Sorrento:
"On Wednesday, Sorrento’s subsidiary SCILEX Pharmaceuticals received FDA approval under a 505(B)(2)
for ZTlido, a lidocaine adhesive patch intended for the treatment ofshingles-related pain. The approval shows SCILEX’s persistence with regulators has paid off; in 2016, ZTlido received a complete response letter citing deficiencies in equivalency testing and CMC. We view ZTlido as a key pillar in Sorrento’s strategy of hedging high-risk early stage programs with lower-risk, cash generating franchises, and we believe the product could provide Sorrento with meaningful sales revenue (estimated peak US+EU ~$220M) to offset operational expenses. With US approval in hand, we expect similar approvals in EU territories could be achieved beginning in late 2018. We reiterate our Outperform rating and increase our PT to $11"
28.06.2018
Stopped prediction by tamam for Sorrento Therapeutics Inc.
Sorrento Therapeutics Inc.
16.05.20
27.06.20
27.06.20
Sorrento Therapeutics Inc.
15.05.20
15.05.20
15.05.20
Sorrento Therapeutics Inc.
29.01.20
15.05.20
15.05.20